Autopsy report · NCT01262664

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

“Terminated per PI's request”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months before it started.
• Ran for about 6 years 7 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Prohibitin-TP01

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
  “Terminated per the PI's request.” (88% match in meaning)
• Effectiveness of an Online Intervention Targeting Cancer-related Fatigue
  “Terminated Per PI” (81% match in meaning)
• Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone
  “terminated by PI” (74% match in meaning)
• Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
  “Closed at PI's Request” (66% match in meaning)
• A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy
  “Feasibility of study. PI termination” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.